Yaohua Zhang

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study.

Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study.

Journal: JAAD international

Published: November 17, 2025

Early Response to Vunakizumab at Week 2 Predicts Favourable Long-Term Efficacy in Patients With Moderate-To-Severe Plaque Psoriasis: A Post Hoc Analysis of a Phase III, Randomised Controlled Trial.

Early Response to Vunakizumab at Week 2 Predicts Favourable Long-Term Efficacy in Patients With Moderate-To-Severe Plaque Psoriasis: A Post Hoc Analysis of a Phase III, Randomised Controlled Trial.

Journal: Immunology

Published: September 11, 2025

Beyond depigmentation: A cross-sectional study of 5227 Chinese patients with vitiligo.

Beyond depigmentation: A cross-sectional study of 5227 Chinese patients with vitiligo.

Journal: The Journal of investigative dermatology

Published: August 19, 2025

Topical ruxolitinib ± oral baricitinib in the treatment of active non-segmental vitiligo: A retrospective analysis.

Topical ruxolitinib ± oral baricitinib in the treatment of active non-segmental vitiligo: A retrospective analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 17, 2025

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo.

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo.

Journal: JAAD international

Published: July 21, 2025

Efficacy of ruxolitinib cream at different body sites in Chinese patients with nonsegmental vitiligo.

Efficacy of ruxolitinib cream at different body sites in Chinese patients with nonsegmental vitiligo.

Journal: Journal of the American Academy of Dermatology

Published: May 21, 2025

Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo.

Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo.

Journal: Journal of the American Academy of Dermatology

Published: October 29, 2024

Efficacy and safety of secukinumab in Chinese patients with psoriasis: Update of six-year real-world data and a meta-analysis.

Efficacy and safety of secukinumab in Chinese patients with psoriasis: Update of six-year real-world data and a meta-analysis.

Journal: Chinese medical journal

Published: October 24, 2024

Huang Lian Jie Du Decoction enhances the anti-tumor efficacy of immune checkpoint inhibitors by activating TLR7/8 signalling in melanoma.

Huang Lian Jie Du Decoction enhances the anti-tumor efficacy of immune checkpoint inhibitors by activating TLR7/8 signalling in melanoma.

Journal: BMC complementary medicine and therapies

Published: October 30, 2023

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis.

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis.

Journal: Chinese medical journal

Published: February 02, 2023

Association of the Polymorphism rs13259960 in SLEAR With Predisposition to Systemic Lupus Erythematosus.

Association of the Polymorphism rs13259960 in SLEAR With Predisposition to Systemic Lupus Erythematosus.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: April 22, 2019

Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.

Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.

Journal: Archives of dermatological research

Published: December 24, 2018

Showing 1-12 of 21

Last Updated: 09/26/2026